Cargando…
Targeting Inflammatory Signaling in Prostate Cancer Castration Resistance
Although castration-resistant prostate cancer (CRPC) as a whole, by its name, refers to the tumors that relapse and/or regrow independently of androgen after androgen deprivation therapy (ADT), untreated tumor, even in early-stage primary prostate cancer (PCa), contains androgen-independent (AI) PCa...
Autores principales: | Zhong, Shangwei, Huang, Changhao, Chen, Zhikang, Chen, Zihua, Luo, Jun-Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584457/ https://www.ncbi.nlm.nih.gov/pubmed/34768524 http://dx.doi.org/10.3390/jcm10215000 |
Ejemplares similares
-
Choosing Kinase Inhibitors for Androgen Deprivation Therapy-Resistant Prostate Cancer
por: Zhong, Shangwei, et al.
Publicado: (2022) -
Targeting INMT and interrupting its methylation pathway for the treatment of castration resistant prostate cancer
por: Zhong, Shangwei, et al.
Publicado: (2021) -
Tumor-derived OBP2A promotes prostate cancer castration resistance
por: Jeong, Ji-Hak, et al.
Publicado: (2022) -
Targeting Tumor Microenvironment by Small-Molecule Inhibitors
por: Zhong, Shangwei, et al.
Publicado: (2019) -
Targeting molecular resistance in castration-resistant prostate cancer
por: Chandrasekar, Thenappan, et al.
Publicado: (2015)